Table of contents
Anal cancer
Background
Overview
Definition
Anal squamous cell cancer is a neoplastic disease arising from malignant transformation of squamous cells found in the mucosa of the anal canal and anal margin.
1
Pathophysiology
The majority of anal squamous cell cancers are caused by infection with oncogenic strains of HPV, particularly types 16 and 18. These strains of HPV encode tumor suppressor proteins E6 and E7, and their interactions with intracellular proteins p53 and retinoblastoma lead to changes in cell growth and regulation, apoptosis, and immortalization, leading to malignant disease.
1
Epidemiology
The incidence of anal squamous cell cancer in the US is estimated at 1.3 cases per 100,000 person-years.
2
Disease course
Initially, anal squamous cell cancer undergoes locoregional spread, with early involvement of the anal musculature, which is very close to the underlying sphincters. Anal canal cancer grows circumferentially, which may result in stenosis of the anal sphincter. When the sphincter is invaded, the tumor spreads into the ischiorectal fossae, the prostatic urethra and bladder in men, and the vagina in women. Anal cancer may spread via the lymphatic vessels to the perirectal nodes or to nodes at the bifurcation of the superior rectal artery. Hematogenous spread occurs in < 10% of cases, and liver metastasis is more common than lung or bone metastasis. Metastasis to distant organs such as the brain and iris has also been reported.
3
Prognosis and risk of recurrence
The 5-year survival rate of patients with T1-T2 anal squamous cell cancer is estimated at 80-90%, while it is estimated at 50% for patients with T4 disease.
3
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of anal cancer are prepared by our editorial team based on guidelines from the American Academy of Family Physicians (AAFP 2024), the Society for Immunotherapy of Cancer (SITC 2023), the European Society of Medical Oncology (ESMO 2021), the American Society of Colon and Rectal Surgeons (ASCRS 2018), and the British HIV ...
Show more
Screening and diagnosis
Diagnostic investigations
History and physical examination
As per ESMO 2021 guidelines:
Perform digital anorectal examination for the detection of lesions in the anal area.
A
Perform clinical examination, including DRE (and vaginal examination in female patients) and palpation of the inguinal lymph nodes, for the assessment of tumor extent.
B
More topics in this section
Diagnostic imaging
HPV testing
HIV testing
Screening for other intraepithelial neoplasia
Diagnostic procedures
Endoscopy: as per ASCRS 2018 guidelines, perform endoscopic evaluation to determine tumor extension and assess for metastatic disease.
B
More topics in this section
FNA
Biopsy and pathology
Medical management
General principles: as per ESMO 2021 guidelines, refer and discuss all patients with anal tumors in a multidisciplinary team meeting with a pre-specified interest in anal cancer.
B
More topics in this section
Management of in-situ lesions
Management of local/locoregional disease (indications)
Management of local/locoregional disease (radiotherapy techniques and doses)
Management of anal margin involvement
Management of advanced/metastatic disease (chemotherapy)
Management of advanced/metastatic disease (immunotherapy/targeted therapy)
Management of advanced/metastatic disease (surgery and local therapies)
Therapeutic procedures
Endoscopic ablation: as per ASCRS 2018 guidelines, consider performing ablative therapy with conventional anoscopy or high-resolution anoscopy in patients with high-grade squamous intraepithelial lesions.
C
More topics in this section
Colostomy
Surgical interventions
Wide-local excision: as per ESMO 2021 guidelines, consider performing local excision for definite treatment of patients with early anal margin cancer (cT1N0M0) aiming to achieve histological clearance of > 1 mm without damaging the anal sphincter muscle.
C
More topics in this section
Abdominoperineal resection